1.Evaluation of Silicone-Based Gel for the Treatment of Hypertrophic Scarring in Rat Models
So-Jeong YIM ; Da-Ye NAM ; Da-Hye CHOI ; Jin WOO ; Youngtae KIM ; JungHoon CHAE ; Young-Shin LEE ; Ji-Youl JUNG
Journal of Wound Management and Research 2024;20(2):122-127
Background:
Hypertrophic scarring represents an aberrant response to wounds in certain individuals, manifesting with symptoms such as itching, tenderness, pain, and pigmentation. This study aimed to investigate the impact of a silicone-based gel on the healing of hypertrophic scars, particularly those originating from deep tissue wounds.
Methods:
A rat model of wound healing and scarring was established, and 12 rats were randomly assigned to three groups: Dermatix Ultra group, SFG-100 silicone-gel group, and non-treated group. Rats in the treated groups (Dermatix Ultra and SFG-100 silicone-gel) received twice-daily applications for 8 weeks. Histologic analysis, including biopsy, was conducted to evaluate the scar elevation index, epidermis thickness, and the number of granulation veins.
Results:
Overall, both the Dermatix Ultra and SFG-100 silicone-gel groups exhibited improvements in hypertrophic scar healing, accompanied by a significant reduction in skin pigmentation. Histopathologically, scars in both treated groups displayed a notable decrease in scar elevation index, epithelial thickness, and collagen disorganization compared to the non-treated group. However, no significant difference was observed between the Dermatix Ultra and SFG-100 silicone-gel groups.
Conclusion
The results suggest that SFG-100 silicone-gel is an effective therapeutic agent for hypertrophic scars. Further research is warranted to elucidate the mechanisms underlying its efficacy and to optimize its application for clinical use.
2.2022 Seoul Consensus on Clinical Practice Guidelines for Functional Constipation
Young Sin CHO ; Yoo Jin LEE ; Jeong Eun SHIN ; Hye-Kyung JUNG ; Seon-Young PARK ; Seung Joo KANG ; Kyung Ho SONG ; Jung-Wook KIM ; Hyun Chul LIM ; Hee Sun PARK ; Seong-Jung KIM ; Ra Ri CHA ; Ki Bae BANG ; Chang Seok BANG ; Sung Kyun YIM ; Seung-Bum RYOO ; Bong Hyeon KYE ; Woong Bae JI ; Miyoung CHOI ; In-Kyung SUNG ; Suck Chei CHOI ;
Journal of Neurogastroenterology and Motility 2023;29(3):271-305
Chronic constipation is one of the most common digestive diseases encountered in clinical practice. Constipation manifests as a variety of symptoms, such as infrequent bowel movements, hard stools, feeling of incomplete evacuation, straining at defecation, a sense of anorectal blockage during defecation, and use of digital maneuvers to assist defecation. During the diagnosis of chronic constipation, the Bristol Stool Form Scale, colonoscopy, and a digital rectal examination are useful for objective symptom evaluation and differential diagnosis of secondary constipation. Physiological tests for functional constipation have complementary roles and are recommended for patients who have failed to respond to treatment with available laxatives and those who are strongly suspected of having a defecatory disorder. As new evidence on the diagnosis and management of functional constipation emerged, the need to revise the previous guideline was suggested. Therefore, these evidence-based guidelines have proposed recommendations developed using a systematic review and meta-analysis of the treatment options available for functional constipation. The benefits and cautions of new pharmacological agents (such as lubiprostone and linaclotide) and conventional laxatives have been described through a meta-analysis. The guidelines consist of 34 recommendations, including 3 concerning the definition and epidemiology of functional constipation, 9 regarding diagnoses, and 22 regarding managements. Clinicians (including primary physicians, general health professionals, medical students, residents, and other healthcare professionals) and patients can refer to these guidelines to make informed decisions regarding the management of functional constipation.
3.Risk of Hepatitis C Virus Transmission through Acupuncture: A Systematic Review and Meta-Analysis
Myung Han HYUN ; Ji Hoon KIM ; Jeong Won JANG ; Jeong Eun SONG ; Do Seon SONG ; Hye Won LEE ; Young Youn CHO ; Gi-Ae KIM ; Eileen L. YOON ; Dong Hyun SINN ; Soon Sun KIM ; Sun Young YIM ; Hyun YANG ; Jihyun AN
The Korean Journal of Gastroenterology 2023;82(3):127-136
Background/Aims:
Chronic hepatitis C is a major risk factor for liver cirrhosis, hepatocellular carcinoma, and hepatic failure. Although traditional practices, including acupuncture, tend to increase the risk of HCV infection, the association remains controversial. Therefore, the current meta-analytical study was undertaken to evaluate the risks of acupuncture and hepatitis C transmission.
Methods:
Two researchers independently screened studies from the databases encompassing the period from inception to May 12, 2022. Baseline demographics, HCV transmission OR, and 95% CIs were extracted, pooled, and analyzed using random-effect models.Subgroup analyses utilizing study design and ethnicity were performed. Heterogeneity and publication bias were analyzed using the Higgins I2 test and funnel plots, respectively.
Results:
In all, 28 studies with 194,826 participants (178,583 controls [91.7%] vs. 16,243 acupuncture users [8.3%]) were included in the final analysis. The pooled analysis showed that acupuncture users had a significantly higher HCV transmission rate than controls with heterogeneity (OR, 1.84 [1.46–2.32]; p<0.001; I2 =80%). In the subgroup analysis, both cross-sectional case-control (n=14; OR, 1.96 [1.47–2.61]; p<0.001; I2 =88%) and cross-sectional studies (n=12; OR, 1.85 [1.32–2.61]; p<0.001; I2 =0%) showed significantly higher HCV infection rates in the acupuncture group than in the control group. Both Asian and non-Asian acupuncture users showed a higher HCV transmission risk than the controls (all Ps <0.001). No significant publication bias was observed.
Conclusions
Our findings indicate that acupuncture increases the risk of HCV transmission. Due to HCV's contagiousness, unsafe medical and social practices (including acupuncture) should be performed with caution.
5.A Foundation for a “Cheerful Society”: The Korean War and the Rise of Psychiatry
Korean Journal of Medical History 2023;32(2):553-591
One of the most remarkable medical achievements of the Korean War was the development of psychiatry. During the Korean War, soldiers and prisoners of war (POWs) experienced “gross stress reaction” and manifested poor concentration and memory as well as clinical depression and social alienation. Rest and relaxation rotations served as the primary treatment for their conditions. Civilians also bore the brunt of the war’s effects. Delusions of grandeur and megalomania appear to have been common among Koreans, but there were few mental health facilities to provide treatment and care. Out of the furnace of war, psychiatry emerged as a newly specialized field, and in the 1950s, Korea became the very place where military psychiatry training under the U.S. military laid the groundwork for civilian psychiatry. This essay aims to enrich the study of mental illness during and after the Korean War by providing a more detailed picture of the mental problems experienced not only by veterans and POWs, but also by civilians in Korea. Examining mental health issues from this period is challenging due to the scarcity of resources for delving into the minds of the civilians involved. Taking military psychiatry as a starting point, this essay goes beyond existing scholarship to discuss psychiatry-related responses to the Korean War, including the influence of military psychiatry on civilian psychiatry, the endeavors of medical professionals and government policies, and contemporary expressions of mental distress during and after the war.
6.Dexamethasone Interferes with Autophagy and Affects Cell Survival in Irradiated Malignant Glioma Cells
Alfred KOMAKECH ; Ji-Hye IM ; Ho-Shin GWAK ; Kyue-Yim LEE ; Jong Heon KIM ; Byong Chul YOO ; Heesun CHEONG ; Jong Bae PARK ; Ji Woong KWON ; Sang Hoon SHIN ; Heon YOO
Journal of Korean Neurosurgical Society 2020;63(5):566-578
Objective:
: Radiation is known to induce autophagy in malignant glioma cells whether it is cytocidal or cytoprotective.Dexamethasone is frequently used to reduce tumor-associated brain edema, especially during radiation therapy. The purpose of the study was to determine whether and how dexamethasone affects autophagy in irradiated malignant glioma cells and to identify possible intervening molecular pathways.
Methods:
: We prepared p53 mutant U373 and LN229 glioma cell lines, which varied by phosphatase and tensin homolog (PTEN) mutational status and were used to make U373 stable transfected cells expressing GFP-LC3 protein. After performing cell survival assay after irradiation, the IC50 radiation dose was determined. Dexamethasone dose (10 µM) was determined from the literature and added to the glioma cells 24 hours before the irradiation. The effect of adding dexamethasone was evaluated by cell survival assay or clonogenic assay and cell cycle analysis. Measurement of autophagy was visualized by western blot of LC3-I/LC3-II and quantified by the GFP-LC3 punctuated pattern under fluorescence microscopy and acridine orange staining for acidic vesicle organelles by flow cytometry.
Results:
: Dexamethasone increased cell survival in both U373 and LN229 cells after irradiation. It interfered with autophagy after irradiation differently depending on the PTEN mutational status : the autophagy decreased in U373 (PTEN-mutated) cells but increased in LN229 (PTEN wild-type) cells. Inhibition of protein kinase B (AKT) phosphorylation after irradiation by LY294002 reversed the dexamethasone-induced decrease of autophagy and cell death in U373 cells but provoked no effect on both autophagy and cell survival in LN229 cells. After ATG5 knockdown, radiation-induced autophagy decreased and the effect of dexamethasone also diminished in both cell lines. The diminished autophagy resulted in a partial reversal of dexamethasone protection from cell death after irradiation in U373 cells; however, no significant change was observed in surviving fraction LN229 cells.
Conclusion
: Dexamethasone increased cell survival in p53 mutated malignant glioma cells and increased autophagy in PTENmutant malignant glioma cell but not in PTEN-wildtype cell. The difference of autophagy response could be mediated though the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling pathway.
7.Associations between Intraocular Pressure and Systemic Parameters according to the KNHNES 2008-2011.
Ji Young LEE ; Hye Bin YIM ; Kwi Young KANG ; Na Young LEE
Journal of the Korean Ophthalmological Society 2017;58(4):430-436
PURPOSE: In this study, we evaluated the associations between intraocular pressure (IOP) and systemic and socioeconomic factors. METHODS: A population-based cross-sectional study using a nation-wide, stratified, multistage, clustered sampling method included 15,421 subjects aged ≥20 years with no history of ocular surgery or glaucoma who participated in the Korean National Health and Nutritional Examination Survey 2008-2011. RESULTS: Univariate regression analyses showed statistically significant linear relationships between IOP and body mass index (BMI), smoking status, heavy drinking, systolic blood pressure, fasting blood glucose, total cholesterol, triglycerides, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), metabolic syndrome (p < 0.001, respectively), low density lipoprotein cholesterol (p = 0.003), refractive error (p < 0.001), and office work (p = 0.029). In addition, analysis of variance (ANOVA) showed statistically significant differences in IOP and refraction according to occupation (p < 0.001, all). CONCLUSIONS: We concluded that increased IOP was associated with age, BMI, heavy drinking, systolic blood pressure, total cholesterol, and refraction. There were statistically significant differences in IOP and refraction according to occupation.
Blood Glucose
;
Blood Pressure
;
Body Mass Index
;
Cholesterol
;
Cholesterol, LDL
;
Cross-Sectional Studies
;
Drinking
;
Fasting
;
Glaucoma
;
Homeostasis
;
Insulin
;
Insulin Resistance
;
Intraocular Pressure*
;
Methods
;
Occupations
;
Refractive Errors
;
Smoke
;
Smoking
;
Socioeconomic Factors
;
Triglycerides
8.An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Eileen L YOON ; Jong Eun YEON ; Eunjung KO ; Hyun Jung LEE ; Ji Hye JE ; Yang Jae YOO ; Seong Hee KANG ; Sang Jun SUH ; Ji Hoon KIM ; Yeon Seok SEO ; Hyung Joon YIM ; Kwan Soo BYUN
Journal of Korean Medical Science 2017;32(2):212-220
The prognostic role of aberrant serum miRNA expression for predicting response to sorafenib treatment in advanced hepatocellular carcinoma (HCC) patients has not been well characterized. We aimed to identify specific serum miRNAs that are associated with positive radiologic responses or improved survival in sorafenib-treated HCC patients. miR-18a, miR-21, miR-139-5p, miR-221, miR-224, and miR-10b-3p, were selected for analysis. Serum samples from 24 patients with advanced stage HCC and 25 patients with liver cirrhosis (LC) were analyzed. All of the miRNAs except miR-21 were found to be upregulated in serum samples from HCC patients. None of the miRNAs assayed differed significantly in terms of expression between the responder and non-responder groups among HCC patients. However, miR-10b-3p levels were significantly higher in the subgroup of HCC patients with worse overall survival (fold change = 5.8, P = 0.008). Serum miRNA-10b-3p was upregulated in the presence of macrovascular invasion (MVI), and those with higher serum miRNA-10b-3p had significantly shorter survival during treatment (P = 0.042). Although no single serum miRNA was predictive of response to sorafenib treatment, analysis of serum miR-10b-3p levels may be valuable for diagnosis of HCC and prediction of survival of sorafenib-treated patients.
Carcinoma, Hepatocellular*
;
Diagnosis
;
Humans
;
Liver Cirrhosis
;
MicroRNAs
9.Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib.
Dae Ha KIM ; Gee Ho MIN ; Dong Won LEE ; Ke Ryun AHN ; Ji Hye KIM ; Sang Jun SUH ; Young Kul JUNG ; Hyung Joon YIM
Journal of Liver Cancer 2016;16(1):57-62
Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically significant improvement in overall survival for patients with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or complete response reported in the previous studies. We herein report a case of dramatic partial response in a patient who had advanced HCC with multiple lung metastasis and portal vein thrombosis treated with sorafenib.
Carcinoma, Hepatocellular*
;
Drug Therapy
;
Humans
;
Lung*
;
Neoplasm Metastasis*
;
Phosphotransferases
;
Protein-Tyrosine Kinases
;
Receptors, Vascular Endothelial Growth Factor
;
Treatment Outcome
;
Venous Thrombosis
10.Clinical and Hematological Effects of Tocilizumab on Serum Hepcidin, Anemia Response and Disease Activity in Patients with Active Rheumatoid Arthritis.
Ki Jeong PARK ; Hye Mi JIN ; Young Nan CHO ; Jeong Hwa KANG ; Hyun Ju JUNG ; Ji Hyoun KANG ; Ji Eun KIM ; Yi Rang YIM ; Jeong Won LEE ; Kyung Eun LEE ; Dong Jin PARK ; Tae Jong KIM ; Shin Seok LEE ; Seung Jung KEE ; Yong Wook PARK
Journal of Rheumatic Diseases 2016;23(1):37-46
OBJECTIVE: The purpose of this study is to evaluate the clinical and hematological effects of tocilizumab in active rheumatoid arthritis (RA) patients. METHODS: Fourteen patients with active RA were enrolled in this study. The patients received tocilizumab 8 mg/kg intravenously every four weeks for 6 months. Disease activity, anemia-related factors including serum hepcidin-25, and hematological parameters were monitored at baseline and at 1, 3, and 6 months after the initiation of treatment. RESULTS: Significant reductions in tender joint count, swollen joint count, visual analogue scale, erythrocyte sedimentation rate (ESR), and C-reactive (CRP) protein plus reductions in a 28-joint disease activity score were observed within one month after the first tocilizumab treatment. These effects lasted throughout the six-month study period. In addition, significant improvements in anemia-related factors such as hepcidin-25, ferritin, iron, hemoglobin, red blood cell counts and mean corpuscular volume were observed during the treatment period. Hematological parameters were improved with reductions in counts for leukocytes, monocytes, neutrophils, and platelets. The lymphocyte counts and their subset numbers were unchanged. Changes in hepcidin levels showed significant correlation with changes in CRP, ESR, ferritin, hemoglobin and counts for red blood cells, leukocytes, and neutrophils during the treatment period. CONCLUSION: This study demonstrates that tocilizumab significantly and meaningfully reduces disease burden in patients with active RA. In addition, tocilizumab diminishes the levels of inflammatory anemia by inhibiting hepcidin production. These clinical data provide evidence of a favorable outcome from tocilizumab in RA.
Anemia*
;
Arthritis, Rheumatoid*
;
Blood Sedimentation
;
Erythrocyte Count
;
Erythrocyte Indices
;
Erythrocytes
;
Ferritins
;
Hepcidins*
;
Humans
;
Iron
;
Joints
;
Leukocytes
;
Lymphocyte Count
;
Monocytes
;
Neutrophils

Result Analysis
Print
Save
E-mail